Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Moderate Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received an average rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $39.25.

A number of research analysts have commented on STOK shares. Wedbush increased their price objective on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. Wolfe Research started coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target for the company. Chardan Capital upped their price objective on Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Loop Capital set a $35.00 target price on Stoke Therapeutics in a report on Monday, January 5th. Finally, Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, January 5th.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 13,430 shares of Stoke Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.27, for a total value of $433,386.10. Following the completion of the transaction, the director owned 49,124 shares of the company’s stock, valued at $1,585,231.48. The trade was a 21.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, General Counsel Jonathan Allan sold 3,978 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.28, for a total transaction of $128,409.84. Following the sale, the general counsel owned 11,831 shares of the company’s stock, valued at approximately $381,904.68. The trade was a 25.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of STOK. Kestra Advisory Services LLC acquired a new stake in Stoke Therapeutics during the fourth quarter worth about $26,000. Harbour Investments Inc. boosted its stake in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after acquiring an additional 898 shares during the period. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics in the third quarter valued at approximately $41,000. BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period.

Stoke Therapeutics Trading Up 2.4%

Stoke Therapeutics stock opened at $35.48 on Friday. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $39.81. The stock has a market cap of $2.03 billion, a P/E ratio of 52.96 and a beta of 1.07. The stock has a 50 day moving average of $32.19 and a 200-day moving average of $28.94.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.